TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
Not yet recruiting · NCT07836309 · Registry updated 2026-09-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602) | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Not yet recruiting | Not stated | 2026-09-23 | NCT07836309 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Zhongda Hospital | 46 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Zhongda Hospital, School of Medicine, Southeast University | Nanjing | China | 9 |